ClinicalTrials.gg
CompletedNCT00546000Updated Jul 24, 2014Results posted

Cutivate Lotion HPA Axis Pediatric Study

A Phase 4 interventional study of Fluticasone propionate 0.05% lotion in Atopic Dermatitis, sponsored by Fougera Pharmaceuticals Inc.. Completed at 10 sites in United States. Open to participants aged 3 Months to 12 Months. Per ClinicalTrials.gov, last updated 2014-07-24.

Sponsored by Fougera Pharmaceuticals Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
3 Months to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
328th of 544
56 · median 96
Started
2007
with 8 others
Phase 4
70 of 639
11 open now
Registered
32nd of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 328th largest by enrollment of the 544 interventional ones that give a count, is one of 9 that started in 2007, is one of 70 in phase 4, and was the 32nd registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 3 Months to 12 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
3 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are 3-12 months of age
  • Subjects diagnosed with Atopic Dermatitis (AD) and have ≥35% of Body Surface Area
  • Subjects meet protocol specific AD signs and symptom severity score

Exclusion criteria

Exclusion Criteria:

  • Subjects with conditions effecting the HPA Axis
  • Subjects with systemic disease
  • Subjects who require treatment with systemic or topical retinoids during the study
  • Subjects who have been treated with various chronic therapies identified in the protocol
  • Subjects who have received other drug treatment within 30 days prior to study entry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    1

    Receive between 22 and 29 days of Cutivate lotion treatment

    Drug: Fluticasone propionate 0.05% lotion

Interventions

06

What researchers measure

Primary outcomes

  1. Post Treatment Serum Cortisol Values Will be Compared.

    The primary safety parameter was the response to the CST at the end of treatment/final visit. Blood samples were collected prior to injection of cosyntropin and post-injection. Post-CST stimulation cortisol level ≤ 18micrograms/dL was considered as evidence of adrenal suppression.

    Time frame: Up to 29 days of treatment

Secondary outcomes

  1. Record Skin Atrophy, Pigmentation Change, Hematological and Chemistry Assessments, and Changes in Atopic Dermatitis Severity

    The frequency distributions of the presence/absence of adverse events associated with signs of atrophy and pigmentation changes were summarized with frequency counts. Hematology and Chemistry Assessments were summarized in shift tables. Signs and symptoms of AD were summarized at each visit.

    Time frame: Over 5-6 visits following the baseline visit through the end of treatment between Day 22-29

07

Results

Posted Jul 24, 2014

Participant flow

Participant flow — Overall Study
MilestoneExperimental
Started56
Completed52
Not completed4
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Baseline hpa axis supression2

Outcome measures

PrimaryPost Treatment Serum Cortisol Values Will be Compared.

The primary safety parameter was the response to the CST at the end of treatment/final visit. Blood samples were collected prior to injection of cosyntropin and post-injection. Post-CST stimulation cortisol level ≤ 18micrograms/dL was considered as evidence of adrenal suppression.

Time frame:
Up to 29 days of treatment
Reported as:
Number · participants
Post Treatment Serum Cortisol Values Will be Compared.
participantsExperimental
Post Treatment Serum Cortisol Values Will be Compared.1
SecondaryRecord Skin Atrophy, Pigmentation Change, Hematological and Chemistry Assessments, and Changes in Atopic Dermatitis Severity

The frequency distributions of the presence/absence of adverse events associated with signs of atrophy and pigmentation changes were summarized with frequency counts. Hematology and Chemistry Assessments were summarized in shift tables. Signs and symptoms of AD were summarized at each visit.

Time frame:
Over 5-6 visits following the baseline visit through the end of treatment between Day 22-29
Reported as:
Number · participants
Record Skin Atrophy, Pigmentation Change, Hematological and Chemistry Assessments, and Changes in Atopic Dermatitis Severity
participantsExperimental
skin atrophy1
pigmentation change9

Adverse events

Collected over 29 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental—1/56 (1.8%)25/56 (44.6%)
Most frequent serious events
Most frequent serious events
EventExperimental
PyrexiaGeneral disorders1/56
Most frequent other events
Showing 10 of 25
Most frequent other events
EventExperimental
PyrexiaGeneral disorders3/56
GastroenteritisInfections and infestations2/56
Herpes simplexInfections and infestations2/56
NasopharyngitisInfections and infestations2/56
Upper respiratory tract infectionInfections and infestations2/56
IrritabilityGeneral disorders2/56
CoughRespiratory, thoracic and mediastinal disorders2/56
HypersensitivityImmune system disorders2/56
FolliculitisInfections and infestations1/56
ImpetigoInfections and infestations1/56

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Experimental
Mean7.2 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)Experimental
Female18
Male38
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental
Hispanic or Latino9
Not Hispanic or Latino47
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(participants)Experimental
American Indian or Alaska Native1
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American31
White19
More than one race7
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Experimental
United States56
08

Study locations

10 sites
  • Centre for Health Care Medical Associates
    Poway, California 92064, United States
  • Rady Children's Hospital, San Diego
    San Diego, California 92123, United States
  • University of Miami, Dept. of Dermatology
    Miami, Florida 33125, United States
  • Adult & Pediatric Dermatology
    Overland Park, Kansas 66211, United States
  • Dermatology Center for Children and Young Adults
    Eagan, Minnesota 55121-1176, United States
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Paddington Testing Company, Inc
    Philadelphia, Pennsylvania 19103, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555-0783, United States
  • University of Texas Health Science Center
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2007
First posted
Oct 18, 2007
Start
Jul 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jul 24, 2014
Last update
Jul 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00546000
Lead sponsor
Fougera Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Oct 18, 2007
Start date
Jul 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jul 24, 2014
Last update
Jul 24, 2014

Study contacts

Alan Fleischer Jr., M.D.
principal investigator · Wake Forest University Health Sciences
Lawrence F. Eichenfield, MD
principal investigator · Rady Children's Hospital, San Diego
Elizabeth Connelly, MD
principal investigator · University of Miami
Craig L. Leonardi, MD
principal investigator · Central Dermatology
Lawrence Parish, MD
principal investigator · Paddington Testing Company, Inc
Adelaide A Hebert, MD
principal investigator · The University of Texas Health Science Center, Houston
Sharon Raimer, MD
principal investigator · University of Texas Medical Branch, Galveston
Kenneth E. Bloom, MD
principal investigator · Dermatology Center for Children and Young Adults
David L Kaplan, MD
principal investigator · Adult & Pediatric Dermatology
Stephen W. Shewmake, M.D.
principal investigator · Centre for Health Care Medical Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion